Updated Phase III analysis show that Itovebi TM (inavolisib) in combination with palbociclib (Ibrance®) and fulvestrant provided a statistically significant and clinically meaningful overall survival benefit in a type of HR-positive advanced breast cancer. This was compared to palbociclib and fulvestrant only.